Leidos Holdings Free cash flow decreased by 40.3% to $270.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 650.0%, from $36.00M to $270.00M. Over 4 years (FY 2021 to FY 2025), Free cash flow shows an upward trend with a 14.9% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q1 '21 | Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $213.00M | $0.00 | $541.00M | $179.00M | $65.00M | $24.00M | $702.00M | $72.00M | -$137.00M | $124.00M | $745.00M | $248.00M | $96.00M | $358.00M | $624.00M | $208.00M | $36.00M | $457.00M | $680.00M | $452.00M | $270.00M |
| QoQ Change | — | -100.0% | — | -66.9% | -63.7% | -63.1% | >999% | -89.7% | -290.3% | +190.5% | +500.8% | -66.7% | -61.3% | +272.9% | +74.3% | -66.7% | -82.7% | >999% | +48.8% | -33.5% | -40.3% |
| YoY Change | — | — | — | — | -69.5% | — | +29.8% | -59.8% | -310.8% | +416.7% | +6.1% | +244.4% | +170.1% | +188.7% | -16.2% | -16.1% | -62.5% | +27.7% | +9.0% | +117.3% | +650.0% |